Page 178 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 178
Chapter 6b
Fig A3. Rituximab trough serum levels.
A, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); B, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B).
Table A1. Central Pathology Review Category for Other Diagnosis or Unclassifiable.
Histology
Indolent B-cell lymphoma
Transformed follicular lymphoma
B-cell lymphoma unclassifiable
Angioimmunoblastic T-cell lymphoma
Transformed nodular lymphocyte-predominant Hodgkin lymphoma Poor-quality sample
No. of Patients
8 6 6 2 1 4
176
